Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yttrium [90Y] Microspheres with Camrelizumab and Apatinib in HCC
NCT07334483Phase 2Recruiting
- Sponsor
- Grand Pharmaceutical Group
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 microspheres in hepatocellular carcinoma (HCC), sponsored by Grand Pharmaceutical Group. Started Aug 2025; status: recruiting.
02
Drugs
yttrium-90 microspheres
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07334483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334483.